In re application of:

## 

ANDERSON et al.

US Natinal	Serial No.:	To Be Assigned	Group Art Unit:
Filed:			Examiner:
International Serial Number: PCT/EP00/09291			Filed: 22 September 2000
Commission	CAMENT DEner for Paten n, D.C. 2023		
		INFORMATION D	ISCLOSURE STATEMENT
Applic Examiner a	ants request t	hat the references identifie nade of record in accordan	d on Form PTO-1449 appended hereto be considered by the ce with the provisions of 37 CFR 1.97
[ ] Co [X ]	pies of the res A copy PCT/El port are listed	of the International Search	parent application Serial No (37 CFR 1.98(d)) n Report which issued on International Application No. erewith. All of the publications cited in the International Search 1-1449 and Applicants understand that copies have been nternational Bureau.
A. [X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).		
OR []	The In of a fir	formation Disclosure Sta	tement submitted herewith is being filed before the mailing filing of a Request For Continued Examination under 37 (4)).
B. []	filing date of of an intern whichever of (1) a f	of the above application or ational application or after event occurred last, but bel inal action under § 1.113 on totice of allowance under §	
[]	Statement v	vas cited in a communicati	em of information contained in this Information Disclosure on from a foreign patent office in a counterpart foreign as prior to the filing of this statement.
[]		ects the option to pay the fortatement under § 1.97(c) (	ee set forth in 37 CFR 1.17(p) for submission of an Information \$240.00).
C. []	1.113, or a	notice of allowance under Also enclosed is a copy of t	t transmitted herewith is being filed after a final action under § § 1.311, whichever occurs first, but before the payment of the the International Search Report which Issued on International

Express Mail No.: EV022025565US



In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [x] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Attorney of Record: James P. RIEK

Registration No. 39,009

GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-<u>8022</u> Facsimile: (919) 483-<u>7988</u>